Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

@inproceedings{Gangadhar2015ClinicalAO,
  title={Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types},
  author={Tara C. Gangadhar and April K. S. Salama},
  booktitle={OncoTargets and therapy},
  year={2015}
}
Preclinical work has led to an increased understanding of the immunomodulatory mechanisms involved in the regulation of the antitumor response in a variety of tumor types. PD-1 (programmed death 1) appears to be a key checkpoint involved in immune suppression in the tumor microenvironment, even in diseases not previously thought to be sensitive to immune manipulation. More recently, the subsequent clinical development of PD-1-based therapy has resulted in a major breakthrough in the field of… CONTINUE READING
1
Twitter Mention

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer

  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 67 REFERENCES

Nivolumab (anti-PD-1; BMS936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial

JR Brahmer, L Horn, S Antonia
  • Presented at: IASLC 15th World Conference on Lung
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

A Ribas, I Puzanov, R Dummer
  • Presented at: Society for Melanoma Research 2014 International Congress, Zurich, Switzerland,
  • 2014
VIEW 1 EXCERPT

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

Antoni Ribas, F. Stephen Hodi, +17 authors Caroline Robert
  • 2014
VIEW 2 EXCERPTS